These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 17164775)

  • 1. Phenotypic correction of alpha-sarcoglycan deficiency by intra-arterial injection of a muscle-specific serotype 1 rAAV vector.
    Fougerousse F; Bartoli M; Poupiot J; Arandel L; Durand M; Guerchet N; Gicquel E; Danos O; Richard I
    Mol Ther; 2007 Jan; 15(1):53-61. PubMed ID: 17164775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic Correction of α-Sarcoglycan Deficiency by Intra-arterial Injection of a Muscle-specific Serotype 1 rAAV Vector.
    Fougerousse F; Bartoli M; Poupiot J; Arandel L; Durand M; Guerchet N; Gicquel E; Danos O; Richard I
    Mol Ther; 2007 Jan; 15(1):53-61. PubMed ID: 28182933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D.
    Rodino-Klapac LR; Lee JS; Mulligan RC; Clark KR; Mendell JR
    Neurology; 2008 Jul; 71(4):240-7. PubMed ID: 18525034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. rAAV vector-mediated sarcogylcan gene transfer in a hamster model for limb girdle muscular dystrophy.
    Li J; Dressman D; Tsao YP; Sakamoto A; Hoffman EP; Xiao X
    Gene Ther; 1999 Jan; 6(1):74-82. PubMed ID: 10341878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant adeno-associated virus type 8-mediated extensive therapeutic gene delivery into skeletal muscle of alpha-sarcoglycan-deficient mice.
    Nishiyama A; Ampong BN; Ohshima S; Shin JH; Nakai H; Imamura M; Miyagoe-Suzuki Y; Okada T; Takeda S
    Hum Gene Ther; 2008 Jul; 19(7):719-30. PubMed ID: 18578595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies.
    Cordier L; Gao GP; Hack AA; McNally EM; Wilson JM; Chirmule N; Sweeney HL
    Hum Gene Ther; 2001 Jan; 12(2):205-15. PubMed ID: 11177557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D.
    Mendell JR; Rodino-Klapac LR; Rosales XQ; Coley BD; Galloway G; Lewis S; Malik V; Shilling C; Byrne BJ; Conlon T; Campbell KJ; Bremer WG; Taylor LE; Flanigan KM; Gastier-Foster JM; Astbury C; Kota J; Sahenk Z; Walker CM; Clark KR
    Ann Neurol; 2010 Nov; 68(5):629-38. PubMed ID: 21031578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I trial of adeno-associated virus serotype 1-γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C.
    Herson S; Hentati F; Rigolet A; Behin A; Romero NB; Leturcq F; Laforêt P; Maisonobe T; Amouri R; Haddad H; Audit M; Montus M; Masurier C; Gjata B; Georger C; Cheraï M; Carlier P; Hogrel JY; Herson A; Allenbach Y; Lemoine FM; Klatzmann D; Sweeney HL; Mulligan RC; Eymard B; Caizergues D; Voït T; Benveniste O
    Brain; 2012 Feb; 135(Pt 2):483-92. PubMed ID: 22240777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rescue of skeletal muscles of gamma-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer.
    Cordier L; Hack AA; Scott MO; Barton-Davis ER; Gao G; Wilson JM; McNally EM; Sweeney HL
    Mol Ther; 2000 Feb; 1(2):119-29. PubMed ID: 10933922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient and long-term intracardiac gene transfer in delta-sarcoglycan-deficiency hamster by adeno-associated virus-2 vectors.
    Li J; Wang D; Qian S; Chen Z; Zhu T; Xiao X
    Gene Ther; 2003 Oct; 10(21):1807-13. PubMed ID: 12960970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delivery of alpha- and beta-sarcoglycan by recombinant adeno-associated virus: efficient rescue of muscle, but differential toxicity.
    Dressman D; Araishi K; Imamura M; Sasaoka T; Liu LA; Engvall E; Hoffman EP
    Hum Gene Ther; 2002 Sep; 13(13):1631-46. PubMed ID: 12228018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic AAV-Mediated β-Sarcoglycan Delivery Targeting Cardiac and Skeletal Muscle Ameliorates Histological and Functional Deficits in LGMD2E Mice.
    Pozsgai ER; Griffin DA; Heller KN; Mendell JR; Rodino-Klapac LR
    Mol Ther; 2017 Apr; 25(4):855-869. PubMed ID: 28284983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not alpha-sarcoglycan deficiency.
    Bartoli M; Poupiot J; Vulin A; Fougerousse F; Arandel L; Daniele N; Roudaut C; Noulet F; Garcia L; Danos O; Richard I
    Gene Ther; 2007 May; 14(9):733-40. PubMed ID: 17330087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mannosidase I inhibition rescues the human alpha-sarcoglycan R77C recurrent mutation.
    Bartoli M; Gicquel E; Barrault L; Soheili T; Malissen M; Malissen B; Vincent-Lacaze N; Perez N; Udd B; Danos O; Richard I
    Hum Mol Genet; 2008 May; 17(9):1214-21. PubMed ID: 18252745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector.
    Greelish JP; Su LT; Lankford EB; Burkman JM; Chen H; Konig SK; Mercier IM; Desjardins PR; Mitchell MA; Zheng XG; Leferovich J; Gao GP; Balice-Gordon RJ; Wilson JM; Stedman HH
    Nat Med; 1999 Apr; 5(4):439-43. PubMed ID: 10202936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epsilon-sarcoglycan compensates for lack of alpha-sarcoglycan in a mouse model of limb-girdle muscular dystrophy.
    Imamura M; Mochizuki Y; Engvall E; Takeda S
    Hum Mol Genet; 2005 Mar; 14(6):775-83. PubMed ID: 15689353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins.
    Mendell JR; Rodino-Klapac LR; Rosales-Quintero X; Kota J; Coley BD; Galloway G; Craenen JM; Lewis S; Malik V; Shilling C; Byrne BJ; Conlon T; Campbell KJ; Bremer WG; Viollet L; Walker CM; Sahenk Z; Clark KR
    Ann Neurol; 2009 Sep; 66(3):290-7. PubMed ID: 19798725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A.
    Bartoli M; Roudaut C; Martin S; Fougerousse F; Suel L; Poupiot J; Gicquel E; Noulet F; Danos O; Richard I
    Mol Ther; 2006 Feb; 13(2):250-9. PubMed ID: 16290124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Systemic Delivery of Adeno-Associated α-Sarcoglycan Gene Transfer for Limb-Girdle Muscular Dystrophy.
    Griffin DA; Pozsgai ER; Heller KN; Potter RA; Peterson EL; Rodino-Klapac LR
    Hum Gene Ther; 2021 Apr; 32(7-8):390-404. PubMed ID: 33349138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of cardiomyopathy in delta-sarcoglycan knockout mice after systemic transfer of targeted adeno-associated viral vectors.
    Goehringer C; Rutschow D; Bauer R; Schinkel S; Weichenhan D; Bekeredjian R; Straub V; Kleinschmidt JA; Katus HA; Müller OJ
    Cardiovasc Res; 2009 Jun; 82(3):404-10. PubMed ID: 19218289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.